Cardiovascular Systems
Innovative cardiovascular solutions for advanced PAD and CAD treatment, enhancing patient outcomes with cutting-edge technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $890m Valuation: $890m 3.6x EV/Revenue -32.7x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 6 % | 14 % | (5 %) | 9 % | (9 %) | 14 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 1 % | 3 % | 2 % | (9 %) | (3 %) | (13 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1 %) | 1 % | - | (12 %) | (5 %) | (16 %) | (8 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 11 % | 12 % | 13 % | 18 % | 16 % | 16 % | - |
Source: Company filings or news article, Equity research estimates
Related Content
Cardiovascular Systems, Inc. (CSI) specializes in developing and providing advanced medical technologies for the treatment of Peripheral Artery Disease (PAD) and Coronary Artery Disease (CAD). The company collaborates with leading healthcare professionals to create innovative solutions that address complex cardiovascular conditions. CSI serves a diverse clientele, including physicians, fellows, cath lab teams, and hospital administrations, primarily within the cardiovascular market. The business model focuses on the development, manufacturing, and distribution of state-of-the-art medical devices designed to improve patient outcomes. Revenue is generated through the sale of these medical devices and related services, supported by clinical evidence and healthcare economics research. CSI's commitment to quality and individualized patient care sets it apart in the industry.
Keywords: Cardiovascular, PAD, CAD, medical technology, healthcare professionals, patient outcomes, clinical evidence, healthcare economics, innovative solutions, medical devices.
Tech stack
Investments by Cardiovascular Systems
Edit